Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

This study is ongoing, but not recruiting participants.
Alzheimer's Disease Cooperative Study (ADCS)
Information provided by (Responsible Party):
Sangamo Therapeutics Identifier:
First received: April 3, 2009
Last updated: January 6, 2017
Last verified: January 2017

The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve cells in the brain function better. CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and protect them from dying. The virus used in CERE-110 does not cause disease in people. CERE-110 has been carefully studied in laboratory animals and is in the early stages of being tested in people.

Fifty patients with mild to moderate Alzheimer's disease will participate in this study. Half of the study subjects will have CERE-110 injected into the brain during a surgical procedure, while the other half will undergo a "placebo" surgery where no medication will be injected. All study participants will be followed for at least two years after surgery.

Condition Intervention Phase
Alzheimer's Disease
Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF
Procedure: Placebo Surgery
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Sangamo Therapeutics:

Primary Outcome Measures:
  • Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) [ Time Frame: 24 Months ]

Secondary Outcome Measures:
  • Neuropsychological Test Battery [ Time Frame: 24 Months ]
  • Mini-Mental State Examination (MMSE) [ Time Frame: 24 Months ]
  • Neuropsychiatric Inventory (NPI) [ Time Frame: 24 Months ]
  • Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) [ Time Frame: 24 Months ]

Estimated Enrollment: 50
Study Start Date: September 2009
Estimated Study Completion Date: March 2020
Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CERE-110
CERE-110: Adeno-Associated Virus Delivery of NGF
Genetic: CERE-110: Adeno-Associated Virus Delivery of NGF
CERE-110 2.0 X 10^11 vg
Sham Comparator: Placebo
Placebo Surgery
Procedure: Placebo Surgery
Placebo Surgery


Ages Eligible for Study:   55 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of mild to moderate Alzheimer's disease
  • Approved medications for Alzheimer's disease may be taken if the dose has been stable for 3 months
  • A study partner who can attend all study visits
  • Good general health
  • Medically able to undergo neurosurgery

Exclusion Criteria:

  • Significant neurological disease other than Alzheimer's disease
  • Significant depression or other psychiatric disorder
  • Unstable medical conditions
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00876863

United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35294
United States, California
University of California, Los Angeles
Los Angeles, California, United States, 90095
University of California, San Diego
San Diego, California, United States, 92037
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20007
United States, Georgia
Emory University
Atlanta, Georgia, United States, 30325
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, North Carolina
Duke University
Durham, North Carolina, United States, 27710
United States, Ohio
Case Western Reserve University
Cleveland, Ohio, United States, 44120
United States, South Carolina
Medical University of South Carolina
North Charleston, South Carolina, United States, 29406
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84108
Sponsors and Collaborators
Sangamo Therapeutics
Alzheimer's Disease Cooperative Study (ADCS)
Study Director: Paul S. Aisen, M.D. Alzheimer's Disease Cooperative Study (ADCS)
  More Information

Responsible Party: Sangamo Therapeutics Identifier: NCT00876863     History of Changes
Other Study ID Numbers: CERE-110-03
NIH Grant 1R01AG030048-01A1
Study First Received: April 3, 2009
Last Updated: January 6, 2017

Keywords provided by Sangamo Therapeutics:
Alzheimer's disease
Memory loss
Cognitive impairment
Nerve growth factor
Neurotrophic factors
Gene therapy

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on April 28, 2017